<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05009654</url>
  </required_header>
  <id_info>
    <org_study_id>NCN_ROL</org_study_id>
    <secondary_id>2014/15/B/NZ7/00893</secondary_id>
    <nct_id>NCT05009654</nct_id>
  </id_info>
  <brief_title>The Effect of Leucine on Carnitine Transport to Skeletal Muscle</brief_title>
  <acronym>ROL</acronym>
  <official_title>Carnitine Supplementation and Skeletal Muscle Function in Aging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gdansk University of Physical Education and Sport</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical University of Gdansk</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gdansk University of Physical Education and Sport</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of the current research project is to explore whether leucine stimulates&#xD;
      carnitine transport, and thus affecting muscle carnitine content.&#xD;
&#xD;
      A secondary aim of this project is to investigate the effect of carnitine with leucine&#xD;
      supplementation on muscle strength and body composition.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2016</start_date>
  <completion_date type="Actual">January 31, 2018</completion_date>
  <primary_completion_date type="Actual">May 15, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Muscle Carnitine Concentration using UPLC-MS/MS</measure>
    <time_frame>24 weeks</time_frame>
    <description>vastus lateralis muscle biopsy taken before and after the supplementation procedure (~20 cm proximal to the knee joint using a thin biopsy needle); carnitine concentration determined using ultra performance liquid chromatography - tandem mass spectrometer (UPLC-MS/MS) method</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Muscle Strength using Biodex System 4 Pro dynamometer</measure>
    <time_frame>24 weeks</time_frame>
    <description>Peak torque measured by performing maximum voluntary contractions during isometric knee extension and flexion. The test performed in concentric-concentric mode consisting maximum 4-s knee extensor isometric contraction and maximum 4-s knee flexor isometric contraction, separated by 20-s recovery, repeated three times. Muscle isokinetic strength assessed in 5 repetitions of flexion and extension at a speed of 60°/s. Muscle endurance assessed in 10 repetitions at 300°/s determine the ability of the muscle to maintain the work. Strength testing performed on the Biodex System 4 Pro dynamometer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Composition: Body Fat Mass, Fat Free Mass, and Skeletal Muscle Mass using a bioelectrical impedance analyzer (InBody720).</measure>
    <time_frame>24 weeks</time_frame>
    <description>The InBody720 measures impedance of five segments of the body (each arm, each leg, trunk) at frequencies of 1, 5, 50, 250, 500, and 1000 kHz through the 8-polar tactile-electrode. Based on the impedance, body fat mass, fat free mass, and skeletal muscle mass are calculated.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Muscle Loss</condition>
  <arm_group>
    <arm_group_label>carnitine + leucine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1000 mg L-carnitine with 3000 mg L-leucine per day for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>leucine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4000 mg L-leucine per day for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>L-carnitine</intervention_name>
    <arm_group_label>carnitine + leucine</arm_group_label>
    <other_name>L-carnitine-L-tartrate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>L-leucine</intervention_name>
    <arm_group_label>carnitine + leucine</arm_group_label>
    <arm_group_label>leucine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  must be able to swallow tablets&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  cardiovascular disease&#xD;
&#xD;
          -  liver disease&#xD;
&#xD;
          -  kidney disease&#xD;
&#xD;
          -  neuromuscular disease&#xD;
&#xD;
          -  gastrointestinal disorders (including stomach ulcers and erosions)&#xD;
&#xD;
          -  diabetes&#xD;
&#xD;
          -  other severe chronic diseases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>29 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 5, 2021</study_first_submitted>
  <study_first_submitted_qc>August 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2021</study_first_posted>
  <last_update_submitted>August 11, 2021</last_update_submitted>
  <last_update_submitted_qc>August 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gdansk University of Physical Education and Sport</investigator_affiliation>
    <investigator_full_name>Robert Olek</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

